Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
14/08/2024 13:47
Aug 14 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX PROVIDES UPDATE ON NEW FINDINGS FOR SIGNAL-AD
PHASE
1B/2 TRIAL OF PEPINEMAB IN ALZHEIMER’S DISEASE AND PLANS TO
PURSUE A DEVELOPMENT PARTNERSHIP
* PEPINEMAB WAS WELL-TOLERATED IN AD, CONSISTENT WITH PRIOR
CLINICAL EXPERIENCE IN HD
Source text for Eikon: ID:nGNXGZ6yX
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease